MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.12906

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022

Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease.

Aguillon David, Langella Stephanie, Chen Yinghua, Sanchez Justin S, Su Yi, Vila-Castelar Clara, Vasquez Daniel, Zetterberg Henrik, Hansson Oskar, Dage Jeffrey L, Janelidze Shorena, Chen Kewei, Fox-Fuller Joshua T, Aduen Paula, Martinez Jairo E, Garcia Gloria, Baena Ana, Guzman Claudia, Johnson Keith A, Sperling Reisa A, Blennow Kaj, Reiman Eric M, Lopera Francisco, Quiroz Yakeel T

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD.

METHODS

We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members.

RESULTS

Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function.

DISCUSSION: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials.

HIGHLIGHTS: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.

Для цитирования: Aguillon David, Langella Stephanie, Chen Yinghua, Sanchez Justin S, Su Yi, Vila-Castelar Clara, Vasquez Daniel, Zetterberg Henrik, Hansson Oskar, Dage Jeffrey L, Janelidze Shorena, Chen Kewei, Fox-Fuller Joshua T, Aduen Paula, Martinez Jairo E, Garcia Gloria, Baena Ana, Guzman Claudia, Johnson Keith A, Sperling Reisa A, Blennow Kaj, Reiman Eric M, Lopera Francisco, Quiroz Yakeel T. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022. DOI: 10.1002/alz.12906.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.